Wael Goravey

Dr. Wael Goravey


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
GAGawahir A. Ali
Gawahir A. Ali
Robert BonomoRobert Bonomo
Robert Bonomo
WGWael Goravey
Wael Goravey
KSKhaled M. Shunnar
Khaled M. Shunnar
MNMostafa Najim
Mostafa Najim
AOAli Omrani
Ali Omrani
Purpose: The aim of this study was to explore the clinical, microbiological, and molecular characteristics of Stenotrophomonas maltophilia bacteraemia, outcomes, and risk factors associated with mortality. Methods: This was a nationwide retrospective cohort study of patients with S. maltophilia bacteraemia during the period between January 2017 and December 2021. MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for susceptibility testing, and Illumina for whole genome sequencing. Kaplan–Meier survival analysis and a multivariable Cox regression model were utilized to assess independent predictors of 90-day all-cause mortality. Results: Ninety patients were included, with a median age of 51.5 years (IQR 37–61), and 25.6% were females. The most common underlying medical conditions included diabetes mellitus (42.2%), and haematological malignancy (23.3%); and 64.4% were immunosuppressed. The most common sources of bacteraemia were the respiratory tract (38.9%) and vascular lines (25.6%). In vitro susceptibility rates were highest for trimethoprim-sulfamethoxazole (98.9%), and levofloxacin (61.1%). Sequencing demonstrated extensive genomic heterogeneity, and sul1 gene was detected in only one strain. The most frequent therapy was trimethoprim-sulfamethoxazole, monotherapy (77.8%) or in combinations (6.7%), for a median duration of 10 days (IQR 5–14). All-cause 90-day mortality was 44.4%. Receiving trimethoprim-sulfamethoxazole was associated with improved 90-day survival (log-rank P < 0.001), and was independently associated with lower mortality in the multivariable Cox model (hazard ratio 0.21, 95% confidence interval 0.06 to 0.74). Conclusion: S. maltophilia blood isolates are genomically diverse and remain mostly susceptible to trimethoprim-sulfamethoxazole. Using trimethoprim-sulfamethoxazole for patients with S. maltophilia bacteraemia appears to be associated with improved survival.

3 April 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
GAGawahir Abbas Mohamed Ali
Gawahir Abbas Mohamed Ali
WGWael Goravey
Wael Goravey
"Disseminated Tuberculosis of the Axial Skeleton" published on 03 Apr 2024 by The American Society of Tropical Medicine and Hygiene.